Nogo抗体;Nogo Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of Nogo expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

Nogo antibodies target Nogo-A, a myelin-associated protein identified as a key inhibitor of axonal regeneration in the central nervous system (CNS). Discovered in the early 2000s, Nogo-A is predominantly expressed by oligodendrocytes and neurons. It belongs to the reticulon family and contains two inhibitory domains: Nogo-66 (extracellular) and Nogo-Δ20 (intracellular). Nogo-A binds to the Nogo-66 receptor (NgR1) and paired immunoglobulin-like receptor B (PirB), activating RhoA/ROCK signaling pathways that collapse growth cones and suppress neurite outgrowth, limiting neural repair after injury.

Research showed that neutralizing Nogo-A with antibodies could enhance axonal sprouting and functional recovery in rodent models of spinal cord injury (SCI) or stroke. Anti-Nogo-A antibodies block its inhibitory signaling, promoting plasticity in corticospinal tracts. This led to preclinical optimism, with some antibodies (e.g., ATI355) advancing to early-phase human trials. However, clinical translation has faced challenges, including variable efficacy, limited regenerative capacity in humans, and potential side effects like pain sensitization.

Despite mixed outcomes, Nogo-A remains a therapeutic target alongside other myelin inhibitors (e.g., MAG, OMgp). Current strategies also explore combining antibodies with rehabilitation or targeting downstream signaling molecules. While Nogo antibodies highlight the CNS’s intrinsic repair barriers, their role in clinical neurorecovery continues to evolve.